An inhibitor of cyclin-dependent kinases
Related Products
Alternative(s)
26024Flavopiridol
Isomer(s)
39845P276-00 (hydrochloride)
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Flavopiridol (hydrochloride)

Item No. 10009197

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one, monohydrochloride
CAS Number
131740-09-5
Synonyms
  • Alvocidib
  • HL 275
  • HMR 1275
  • L-868,275
Molecular Formula
C21H20ClNO5 • HCl
Formula Weight
438.3
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 16 mg/mlDMF:PBS (pH 7.2) (1:1): 0.5 mg/mlDMSO: 12.5 mg/mlEthanol: 1.6 mg/ml
λmax
211, 265, 307 nm
SMILES
ClC1=C(C(OC2=C3C(O)=CC(O)=C2[C@H]4CCN(C)C[C@H]4O)=CC3=O)C=CC=C1.Cl
InChi Code
InChI=1S/C21H20ClNO5.ClH/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22;/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3;1H/t12-,17+;/m0./s1
InChi Key
LGMSNQNWOCSPIK-LWHGMNCYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $54

    Add

    10 mg

    $81

    Add

    25 mg

    $158

    Add

    50 mg

    $262

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Flavopiridol is an orally bioavailable inhibitor of cyclin dependent kinases (IC50s = ~100, ~100, ~100, and 300 nM for Cdk1, Cdk2, Cdk4, and Cdk7, respectively).1 It also inhibits TEFb, a complex composed of Cdk9 and cyclin T1, with a Ki value of 3 nM.2 Flavopiridol inhibits transcription of a CMV promoter in HeLa nuclear extract (IC50 = 34 nM), Tat-stimulated transcription of an HIV-1 promotor (IC50 = 7 nM), and HIV-1 replication in HEK239T cells (IC50 = <10 nM). In vivo, flavopiridol (5 mg/kg, i.p.) induces apoptosis and cyclin D1 depletion and delays tumor growth in an HN-12 head and neck carcinoma mouse xenograft model.1 It also suppresses synovial hyperplasia and joint destruction in a mouse model of collagen-induced arthritis.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Senderowicz, A.M., and Sausville, E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 92(5), 376-387 (2000).

    2. Chao, S.H., Fujinaga, K., Marion, J.E., et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. The Journal of Biological Chemisty 275(37), 28345-28348 (2000).

    3. Sekine, C., Sugihara, T., Miyake, S., et al. Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. J. Immunol. 180(3), 1954-1961 (2008).